- Non-small-cell lung cancer – after surgery - adjuvant chemotherapy with or without additonal targeted therapy (bevacizumab).
- Breast cancer – treatment after surgery for patients who have not had their menopause who have hormone sensitive cancer.
- Metastatic breast cancer - comparing 2 dosing schedules of a chemotherapy drug while getting a special targeted therapy (bevacizumab).
- Paroxysmal Nocturnal Hemoglobinuria (PNH) – lab test to find out the percentage of PNH in patients with bone marrow failures.
- Advanced Renal cell (kidney) cancer – different combinations of targeted therapy for kidney cancer that has spread outside the kidney
- Renal cell (kidney) cancer – targeted adjuvant therapy after surgery to prevent recurrence in patients with high risk of their kidney cancer returning.
- Multiple myeloma – comparing effectiveness of 2 treatments.
- Non-Hodgkin's Lymphoma - for intermediate grade B-cell lymphoma , get R-CHOP chemotherapy and then after 3- cycles further treatment decisions are based on PET scan results.
- Facing Forward - guide to make life easier after cancer treatment for breast, colon, rectum, prostate or lung cancer.
- The Smoking Cessation Research Study – comparing nicotine patch and the nicotine lozenge.
- Head and neck cancer – that has come back or spread – new targeted therapy combined with chemotherapy.
Currently recruiting patients:
- Brain cancer – comparing conventional with more intensive dose of temozolomide in glioblastoma.
- Head and neck cancer – comparing concurrent radiation and chemotherapy with or without targeted therapy.
- Breast cancer – comparing whole breast irradiation with partial breast irradiation.
- Bone metastasis – radiopharmaceuticals and Zometa for lung, breast & prostate cancer.
- Painful bone metastasis – single vs multiple smaller doses of irradiation.
- Prostate cancer – radiation - high dose vs standard dose.
- Prostate cancer – radiation and hormone therapy with or without chemotherapy.
- Prostate cancer – Zometa to prevent bone loss for patients on radiation therapy and hormonal therapy
- Prostate cancer – Hormone therapy with radiation of groin lymph nodes or the prostate bed.
- Non-small-cell lung cancer – chemotherapy and high-dose radiation, then surgery followed by more chemotherapy.
- Non-small-cell lung cancer – comparing standard dose and high dose radiation, both with chemotherapy.
- Non-small-cell lung cancer – Selenium in cancer prevention after surgery of stage I non-small-cell lung cancer.
Updated: October 13, 2008
Welcome to SUNY Downstate MB-CCOP
Cancer Clinical Trials
at Brooklyn's SUNY Downstate MB-CCOP
We are funded by the National Cancer Institute (NCI) to bring state-the-art clinical trials in cancer prevention, diagnosis and treatment to the diverse community of Brooklyn. These trials are performed in collaboration with many major cancer research centers across the nation.
At SUNY Downstate MB-CCOP, these cancer clinical trials are conducted at the University Hospital of Brooklyn and Kings County Hospital Center, which are 2 of the primary teaching hospitals of SUNY Downstate Medical Center, conveniently located in the heart of Brooklyn.
This website contains general information about what cancer clinical trials are and what people can expect if they take part in a trial. It also contains specific information on clinical trials that are currently available.
If you have any further questions, or would like more information from us, please contact one of our staff members. We will be very happy to provide you with the information you need.
Thank you for your interest in us.
The SUNY Downstate MB-CCOP Team
____________________________________________________________________________________________
About us | About clinical trials | About cancer treatments | Staff / contacts | Directions | Useful links | Site map
SUNY Downstate MB-CCOP: Bringing state-of-the-art cancer clinical trials to Brooklyn.
Copyright © 2008. All rights reserved.
Congratulations to our MB-CCOP team:
We are the top recruiter in the nation for the Facing Forward Trial in September 2008.
Keep up the good work!
